Blog

High-throughput development is the future of biologics. Biointron outlines innovations that accelerate antibody discovery and production at scale.

High-affinity B cells refine antibody maturation. Biointron explains how they optimize immune responses and support therapeutic antibody development.

ISACs represent a new frontier beyond ADCs. Biointron explores immune-stimulating antibody conjugates and their promise in cancer and immunotherapy.

Therapeutic antibodies have transformed global medicine. Biointron provides a worldwide overview of their development, impact, and future directions.

World ADC 2025 in London spotlighted ADC breakthroughs. Biointron shares highlights from the event, showcasing next-generation conjugate therapies.

Biointron provides CRO services that accelerate antibody discovery, engineering, and development, supporting global biotech programs with reliable expertise.

China’s first national standards on lab animal welfare reshape research practices. Biointron reviews their impact on antibody studies and biotech innovation.

Recombinant proteins replicate natural proteins. Biointron reviews their applications in biotechnology, medicine, and therapeutic antibody development.

Humanizing VHH antibodies reduces immunogenicity. Biointron explains how camelid-derived antibodies are optimized into clinical therapeutics.

Single-domain antibodies hold promise in oncology. Biointron explores their role in tumor immunotherapy and advantages over conventional formats.

Antibody engineering unlocks opportunities and faces challenges. Biointron explains methods to enhance affinity, stability, and therapeutic performance.

Monoclonal antibodies dominate clinical research. Biointron reviews current trends and future outlooks shaping antibody trials worldwide.